224 related articles for article (PubMed ID: 23570185)
21. Clinical trial registration.
Harms M
Physiotherapy; 2011 Sep; 97(3):181. PubMed ID: 21820534
[No Abstract] [Full Text] [Related]
22. SOP 02: Evaluation and selection of a clinical trial proposal for CESAR.
Onkologie; 2003 Oct; 26 Suppl 6():5-10. PubMed ID: 23570178
[No Abstract] [Full Text] [Related]
23. European Commission considers revisions to clinical trials directive.
Mason E
J Natl Cancer Inst; 2010 Mar; 102(5):292-4, 297. PubMed ID: 20173121
[No Abstract] [Full Text] [Related]
24. Reporting harms more transparently in trials of cancer drugs.
Gyawali B; Shimokata T; Honda K; Ando Y
BMJ; 2018 Nov; 363():k4383. PubMed ID: 30385466
[No Abstract] [Full Text] [Related]
25. How to ascertain drug related deaths during clinical trials ?
Lele RD
J Assoc Physicians India; 2013 Oct; 61(10):733-7. PubMed ID: 24772730
[TBL] [Abstract][Full Text] [Related]
26. Sponsors' and investigative staffs' perceptions of the current investigational new drug safety reporting process in oncology trials.
Perez R; Archdeacon P; Roach N; Goodwin R; Jarow J; Stuccio N; Forrest A
Clin Trials; 2017 Jun; 14(3):225-233. PubMed ID: 28345368
[TBL] [Abstract][Full Text] [Related]
27. [Drug development in paediatric oncology].
Benninger-Döring G; Boos J
Klin Padiatr; 2006; 218(3):152-6. PubMed ID: 16688671
[TBL] [Abstract][Full Text] [Related]
28. Clinical trials. Experimental cancer therapies move to the front line.
Couzin-Frankel J
Science; 2012 Jan; 335(6066):282-3. PubMed ID: 22267789
[No Abstract] [Full Text] [Related]
29. The future of monitoring in clinical research - a holistic approach: linking risk-based monitoring with quality management principles.
Ansmann EB; Hecht A; Henn DK; Leptien S; Stelzer HG
Ger Med Sci; 2013; 11():Doc04. PubMed ID: 23382708
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of benefits derived from a computerized data management system for clinical trials data.
Elting LS; Bodey GP
Proc Annu Symp Comput Appl Med Care; 1991; ():48-52. PubMed ID: 1807647
[TBL] [Abstract][Full Text] [Related]
31. Is there room for improvement in adverse event reporting in the era of targeted therapies?
Edgerly M; Fojo T
J Natl Cancer Inst; 2008 Feb; 100(4):240-2. PubMed ID: 18270340
[TBL] [Abstract][Full Text] [Related]
32. Causality Assessment in Premarketing Drug Clinical Trials: Regulatory Evolution in the USA and Ongoing Concerns.
Goldman SA
Drug Saf; 2016 Oct; 39(10):895-901. PubMed ID: 27473417
[TBL] [Abstract][Full Text] [Related]
33. Re: Demand grows for early access to promising cancer drugs.
Genève J
J Natl Cancer Inst; 2003 Mar; 95(6):492. PubMed ID: 12644549
[No Abstract] [Full Text] [Related]
34. Tighter safety controls needed over clinical trials, says FDA.
Am J Health Syst Pharm; 1995 Feb; 52(4):357. PubMed ID: 7757854
[No Abstract] [Full Text] [Related]
35. Multiple Dimensions of Value: Evaluative Frameworks for New Cancer Therapies.
Cheung MC; Sabharwal M; Chambers A; Han D; Sabarre KA; Chan K
J Clin Oncol; 2016 Apr; 34(12):1428-9. PubMed ID: 26884567
[No Abstract] [Full Text] [Related]
36. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the member states relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use.
Med Etika Bioet; 2002; 9(1-2):12-9. PubMed ID: 16276663
[No Abstract] [Full Text] [Related]
37. Centralized medical monitoring in phase III clinical trials: the National Surgical Adjuvant Breast and Bowel Project (NSABP) experience.
Soran A; Nesbitt L; Mamounas EP; Lembersky B; Bryant J; Anderson S; Brown A; Passarello M
Clin Trials; 2006; 3(5):478-85. PubMed ID: 17060221
[TBL] [Abstract][Full Text] [Related]
38. Follow-Up on the Use of Machine Learning in Clinical Quality Assurance: Can We Detect Adverse Event Under-Reporting in Oncology Trials?
Ménard T; Koneswarakantha B; Rolo D; Barmaz Y; Popko L; Bowling R
Drug Saf; 2020 Mar; 43(3):295-296. PubMed ID: 31834590
[No Abstract] [Full Text] [Related]
39. Some thoughts on the reporting of adverse events in phase II cancer clinical trials.
Anderson SJ
J Clin Oncol; 2006 Aug; 24(24):3821-2. PubMed ID: 16921032
[No Abstract] [Full Text] [Related]
40. [ICH-GCP Guideline: quality assurance of clinical trials. Status and perspectives].
Englev E; Petersen KP
Ugeskr Laeger; 2003 Apr; 165(16):1659-62. PubMed ID: 12756823
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
